12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Corcept, Pharmakon Advisors L.P. deal

Corcept granted a Pharmakon Advisors fund rights to receive up to $45 million in royalties on Corcept's products in exchange for $30 million in cash. In April, Corcept launched Korlym mifepristone - its first marketed product...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >